Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Stroke and Myocardial Infarction (MI) in Hereditary Thrombotic Thrombocytopenic Purpura (HTTP): Similarities to Sickle Cell Anemia (SSA)

Azra Borogovac, MD, James George, MD

Blood (2019) 134 (Supplement_1): 1079.

https://doi.org/10.1182/blood-2019-122208

Published: 2019

Journal Articles

Impact of Residual Effects and Complications of Thrombotic Thrombocytopenic Purpura (TTP) on Daily Living: A Qualitative Study

Deirdra Terrell, PhD, Spero Cataland, MD, Laura Beebe, PhD, San Keller, PhD MS, Julie Panepinto, MDMSPH, Sara K. Vesely, PhD MPH, James George, MD, Rachel Ann Kelley, BS, Marshall Cheney, PhD

Blood (2019) 134 (Supplement_1): 931.

https://doi.org/10.1182/blood-2019-128989

Published: 2019

Journal Articles

Genotype-Phenotype Correlation in Congenital TTP: New Insights from a Multicentre Study with 121 Patients

Anette Anette Van Dorland, PhD, Magnus Mansouri Taleghani, MD, Kenneth Dale Friedman, MD, James George, MD, Ingrid Hrachovinova, PhD, Paul Knöbl, MD PhD, Bernhard Lammle, MD, Masanori Matsumoto, MD, Anne Sophie von Krogh, MD, Reinhard Schneppenheim, MDPhD, Isabella Aebi-Huber, Bütikofer Lukas, PhD, Zuzana Cermakova, PhD, Petter Quist-Paulsen, MD PhD, Deirdra Terrell, PhD, Sara K. Vesely, PhD MPH, Yoshihiro Fujimura, MD PhD, Johanna A. Kremer Hovinga Strebel, MD

Blood (2018) 132 (Supplement 1): 376.

https://doi.org/10.1182/blood-2018-99-112095

Published: 2018

Journal Articles

Role of Somatic Mutations and Clonal Thrombopoiesis in Immune Thrombocytopenia

Sami Ibrahimi, MD, James George, MD, Patrick M Gaffney, MD, Sara K. Vesely, PhD MPH, Adam S. Asch, MD

Blood (2018) 132 (Supplement 1): 130.

https://doi.org/10.1182/blood-2018-99-111413

Published: 2018

Journal Articles

Long-Term Safety Profile of Romiplostim in Patients with Chronic Immune Thrombocytopenia (ITP).

Howard Liebman, MD, FACP, David Henry, MD, Francois Lefrere, MD, Jean-Francois Viallard, MD, Alan Lichtin, MD, James George, MD, Miguel Sanz, MD, PhD, Kathy Zhang, PhD, Mark Rutstein, MD

Blood (2008) 112 (11): 3415.

https://doi.org/10.1182/blood.V112.11.3415.3415

Published: 2008

Journal Articles

Self-Injection of Romiplostim by Patients with Chronic Immune Throbocytopenic Purpura (ITP)

James George, MD, James B Bussel, MD, Roger M Lyons, MD, Vinod Pullarkat, MD, Robert Redner, MD, Deirdra Terrell, PhD, Kun Nie, PhD, Dietmar Berger, MD, PhD

Blood (2008) 112 (11): 4707.

https://doi.org/10.1182/blood.V112.11.4707.4707

Published: 2008

Journal Articles

What Level of Platelet Count and Symptoms Trigger Referral of Patients with Thrombocytopenia from Primary Care Physicians to Hematologists?

Deirdra Terrell, PhD, Laura A Beebe, PhD, James W Mold, MD, James George, MD, Sara K. Vesely, PhD

Blood (2008) 112 (11): 4692.

https://doi.org/10.1182/blood.V112.11.4692.4692

Published: 2008

Journal Articles

Evaluation of Bleeding and Thrombotic Events during Long-Term Use of Romiplostim in Patients with Chronic Immune Thrombocytopenic Purpura.

Michael Tarantino, MD, Usha Sunkara, MD, James George, MD, Louis M. Aledort, MD, Matthew Guo, PhD, Dietmar Berger, MD, PhD, Terry Gernsheimer, MD

Blood (2008) 112 (11): 3422.

https://doi.org/10.1182/blood.V112.11.3422.3422

Published: 2008

Journal Articles

Lower ADAMTS13 Activity and Higher Bethesda Units of Antibody Inhibitor in Early Remission Are Associated with a Higher Probability of TTP Exacerbation.

Spero Cataland, Shangbin Yang, April Horne, Shili Lin, James George, MD, Haifeng Wu, MD

Blood (2008) 112 (11): 2299.

https://doi.org/10.1182/blood.V112.11.2299.2299

Published: 2008

Journal Articles

The Prevalence of Immune Thrombocytopenic Purpura (ITP).

Deirdra Terrell, PhD, Laura A Beebe, PhD, James George, MD, Barbara R Neas, PhD, Sara K. Vesely, PhD, Jodi Segal, M.D.

Blood (2008) 112 (11): 1277.

https://doi.org/10.1182/blood.V112.11.1277.1277

Published: 2008

Journal Articles

Long-Term Dosing of AMG 531 in Thrombocytopenic Patients with Immune Thrombocytopenic Purpura: 48-Week Update.

David Kuter, James Bussel, James George, Louis Aledort, Alan Lichtin, Roger Lyons, Jorge Nieva, Jeffrey Wasser, Emanuelle Bourgeois, Mies Kappers-Klunne, Francois Lefrere, Martin Schipperus, Reggie Kelly, Jenny Christal, Matthew Guo, Janet Nichol

Blood (2006) 108 (11): 476.

https://doi.org/10.1182/blood.V108.11.476.476

Published: 2006

Journal Articles

A Phase 2 Placebo Controlled Study Evaluating the Platelet Response and Safety of Weekly Dosing with a Novel Thrombopoietic Protein (AMG531) in Thrombocytopenic Adult Patients (pts) with Immune Thrombocytopenic Purpura (ITP).

David Kuter, MD, DPhil, James B. Bussel, MD, Louis M. Aledort, MD, James George, MD, Roger M. Lyons, MD, George T. Conklin, MD, Alan E. Lichtin, MD, Jorge Nieva, MD, Reggie Kelly, BA, Chien-Feng Chen, PhD, Janet L. Nichol, MS

Blood (2004) 104 (11): 511.

https://doi.org/10.1182/blood.V104.11.511.511

Published: 2004

NARROW

Stroke and Myocardial Infarction (MI) in Hereditary Thrombotic Thrombocytopenic Purpura (HTTP): Similarities to Sickle Cell Anemia (SSA)

Impact of Residual Effects and Complications of Thrombotic Thrombocytopenic Purpura (TTP) on Daily Living: A Qualitative Study

Genotype-Phenotype Correlation in Congenital TTP: New Insights from a Multicentre Study with 121 Patients

Role of Somatic Mutations and Clonal Thrombopoiesis in Immune Thrombocytopenia

Long-Term Safety Profile of Romiplostim in Patients with Chronic Immune Thrombocytopenia (ITP).

Self-Injection of Romiplostim by Patients with Chronic Immune Throbocytopenic Purpura (ITP)

What Level of Platelet Count and Symptoms Trigger Referral of Patients with Thrombocytopenia from Primary Care Physicians to Hematologists?

Evaluation of Bleeding and Thrombotic Events during Long-Term Use of Romiplostim in Patients with Chronic Immune Thrombocytopenic Purpura.

Lower ADAMTS13 Activity and Higher Bethesda Units of Antibody Inhibitor in Early Remission Are Associated with a Higher Probability of TTP Exacerbation.

The Prevalence of Immune Thrombocytopenic Purpura (ITP).

Long-Term Dosing of AMG 531 in Thrombocytopenic Patients with Immune Thrombocytopenic Purpura: 48-Week Update.

A Phase 2 Placebo Controlled Study Evaluating the Platelet Response and Safety of Weekly Dosing with a Novel Thrombopoietic Protein (AMG531) in Thrombocytopenic Adult Patients (pts) with Immune Thrombocytopenic Purpura (ITP).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only